MADRID, 15 Nov (APM) - Financial newspaper Cinco Días carried a lengthy interview on Thursday with Alnylam's head in Spain, who discussed pricing of orphan drugs and talks with the ministry of health to secure reimbursement approval of its amyloidosis therapy Onpattro (patisiran).
Jorge Capapey, head of Alnylam in Spain, spoke about the beginnings of the company and the discovery of RNA interference (RNAi) thecnology-based Onpattro, adding that the company is in pricing talks with the Spanish ministry of health for the reimbursement of the medicine.
He said: "The price will be decided considering that amyloidosis is a rare disease, so few patients will benefit from it."
Capapey told Cinco Días about other Alnylam drugs, including givosiran for patients with acute hepatic porphyria (AHP); lumasiran, an investigational therapy for treating primary hyperoxaluria type 1 (PH1) and inclisiran for reducing LDL-cholesterol levels.
RNAi therapies can be used in a number of different conditions because they are highly specific in the proteins they target. "This is a true revolution, we are just spotting the tip of the iceberg," he said.
Collaborative studies have already started with Regeneron to assess the safety and efficacy of cemdisiran to treat paroxysmal nocturnal haemoglobinuria (PNH) and immunoglobulin A (IgA) nephropathy. With Sanofi, Alnylam is working in the field of haemophilia, he added.
According to Capapey, the firm is focused on obtaining reimbursement for Onpattro in medium-sized countries like France, Italy and Spain, among others. The drug has already been launched in Japan, the UK, Germany and Belgium.
Lilly's Madrid lab's contribution to cancer drugs
On Thursday, financial newspaper Cinco Días carried a story about the contribution of Madrid-based teams in the development of Lilly's Verzenio (abemaciclib) and other drugs with the headline: 'The legacy of R&D in the fight against cancers and diabetes'.
According to Cinco Días, the involvement of Lilly's Spanish workforce in the plant that the firm has near Madrid in the development of Verzenio was substantial at all stages.
Speaking at the celebration of the 35th anniversary of the plant Nabil Daoud, the company head in Spain said that other important medicines have been developed with the contribution of that workforce, including treatments for obesity, diabetes, depression, Alzheimer's, Parkinson's, pain and various immunological conditions.
Two new migraine treatments available in Spain
Daily newspaper El País on Saturday carried a story about the approval of Novartis and Lilly's migraine drugs for reimbursement in Spain. (APMHE 65022
There are limitations to the reimbursement of both medicines, including a minimum of eight migraine episodes in a month and previous treatment with conventional therapies, the newspaper reported.
Both drugs are monoclonal antibodies, a type of medicines which have been used to treat cancer, El País noted.
Almirall owners sell 6% stake, shares fall 10%
Shares of Barcelona-based Almirall dropped after the Gallardo family, which owns 66% of the firm, sold 6.3% of its stock, daily newspaper La Vanguardia, financial newspapers El Economista, Cinco Días, Expansión and medical journal Redacción Médica reported on Wednesday.
The sale was intended to "increase cash and improve visibility", with a 10% discount, via JP Morgan Securities, Expansión reported.
According to the CNMV, the agency which supervises the stock market in Spain, 11 million shares were sold at €15.25 in a €167.75 million operation, Expansión added.
Rapamycin 'prevents age-related brain vascular deterioration'
A new study with mice shows that rapamycin could be used to prevent memory loss associated with age and vascular deterioration in the bran, daily newspaper ABC reported on Saturday.
The newspaper quoted author Candice Van Skike, from Texas University San Antonio as saying that the finding could have implications for aging in general and for the prevention of Alzheimer's disease in some people, the newspaper said.